Designing Long-Term Stability Studies Based on Climatic Zones: A Global Strategy

Pharmaceutical products are distributed across a wide range of geographical regions, each with unique environmental conditions. Long-term stability studies must reflect these regional differences to ensure that drug quality is maintained throughout the product’s lifecycle. Climatic zone-based stability study design, as guided by ICH Q1A(R2), Q1F, and WHO expectations, enables manufacturers to tailor their programs to global markets. This tutorial provides a comprehensive guide to designing long-term stability studies that align with climatic zones, including regulatory requirements, protocol planning, and region-specific considerations.

1. Introduction to Climatic Zones in Stability Testing

Climatic zones are classifications used to group countries and regions based on temperature and humidity patterns. These classifications help determine the appropriate long-term storage conditions under which stability testing should be conducted.

ICH Climatic Zones:

Zone	Description	Long-Term Condition
Zone I	Temperate climate	25°C ± 2°C / 60% RH ± 5%
Zone II	Subtropical and Mediterranean	25°C ± 2°C / 60% RH ± 5%
Zone III	Hot and dry	30°C ± 2°C / 35% RH ± 5%
Zone IVa	Hot and humid	30°C ± 2°C / 65% RH ± 5%
Zone IVb	Very hot and very humid (Tropical)	30°C ± 2°C / 75% RH ± 5%

2. Regulatory Guidelines and Global Applicability

ICH Q1A(R2):

• Provides general principles for long-term and accelerated stability testing
• Allows adaptation to regional zones for long-term storage conditions

ICH Q1F:

• Initially defined stability testing for climatic zones III and IV
• Withdrawn but still referenced by regional regulators

WHO PQ:

• Mandates real-time Zone IVb data for products intended for tropical regions
• Strict requirements for PQ-listed products distributed in Sub-Saharan Africa, Asia, and Latin America

FDA and EMA:

• Zone II (25°C/60% RH) is acceptable for most products marketed in US and EU
• Additional data required if product intended for other climatic zones

3. Selecting the Appropriate Zone for Study Design

The selection of a climatic zone for long-term study depends on the product’s intended market. Manufacturers must:

• Map all target markets to their respective zones
• Select the highest stress condition zone among them
• Design long-term testing at that zone to serve as worst-case data

Example:

If a product is intended for both Europe and Africa, Zone IVb conditions (30°C/75% RH) must be included even though Zone II is sufficient for Europe.

4. Designing the Long-Term Stability Study

Basic Elements:

• Condition: Based on selected climatic zone (e.g., 30°C/75% RH for Zone IVb)
• Duration: Minimum of 12 months for initial filing; 18–36 months for final shelf-life assignment
• Sampling Points: 0, 3, 6, 9, 12, 18, 24, 36 months
• Packaging: Final commercial container-closure system
• Storage: In a qualified and mapped stability chamber

5. Analytical Parameters to Monitor

All critical quality attributes (CQAs) must be assessed, including:

• Assay/potency
• Degradation products/impurities
• Moisture content
• Dissolution (if applicable)
• Appearance, odor, and color
• Container-closure integrity (if required)

6. Risk-Based Zone Selection and Bridging

Some manufacturers use worst-case zones for all global markets to reduce redundancy. Others use bracketing and matrixing to reduce the number of conditions tested. This is acceptable if justified scientifically.

Example:

• Test only Zone IVb if product will be distributed globally
• Use stability modeling to justify extrapolation to Zone II or III

Bridging Strategy:

Products stored in high-barrier packaging may justify fewer zone-specific studies if permeability is demonstrably low.

7. Real-World Case Examples

Case 1: Global Product Qualified Under Zone IVb

A manufacturer conducted long-term studies at 30°C/75% RH for a solid oral product intended for global distribution. FDA, EMA, and WHO PQ accepted the data, eliminating the need for Zone-specific duplications.

Case 2: Shelf Life Rejected for Zone III Only Study

A syrup tested only at 30°C/35% RH for Zone III was submitted to WHO PQ. It was rejected for missing Zone IVb data required for sub-Saharan distribution. The applicant had to repeat long-term studies at 30°C/75% RH.

Case 3: EMA Acceptance of Justified Zone Bridging

A dermal cream tested at Zone IVa showed low impurity growth. The company justified bridging to Zone IVb using forced degradation studies and packaging barrier claims. EMA accepted the strategy, and shelf-life was granted.

8. Tools and SOPs for Zone-Based Stability Programs

Available from Pharma SOP:

• Climatic Zone Mapping and Justification SOP
• ICH Zone-Based Stability Study Protocol Template
• Bridging Study Risk Assessment Form
• Stability Chamber Qualification and Zoning Template

Additional regulatory templates and case walkthroughs can be accessed at Stability Studies.

Conclusion

Climatic zone-based long-term stability study design is a critical component of global regulatory strategy. By aligning testing conditions with the environmental realities of target markets, pharmaceutical manufacturers can ensure compliance, maintain product integrity, and streamline global approvals. An evidence-based, zone-conscious approach not only strengthens shelf-life justifications but also protects patients by ensuring drug quality across all regions.